Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea. It is also involved in the development of generic dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo; and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Israel.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-8931-3433
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$170,000.00
Profitability
Miscellaneous
Employees49
OptionableNot Optionable
Sol Gel Technologies (NASDAQ:SLGL) Frequently Asked Questions
What is Sol Gel Technologies' stock symbol?
Sol Gel Technologies trades on the NASDAQ under the ticker symbol "SLGL."
How were Sol Gel Technologies' earnings last quarter?
Sol Gel Technologies Ltd (NASDAQ:SLGL) released its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.16. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.05 million. View Sol Gel Technologies' Earnings History.
When is Sol Gel Technologies' next earnings date?
What price target have analysts set for SLGL?
4 Wall Street analysts have issued 1 year price targets for Sol Gel Technologies' stock. Their forecasts range from $17.00 to $21.00. On average, they anticipate Sol Gel Technologies' stock price to reach $19.00 in the next year. This suggests a possible upside of 184.0% from the stock's current price. View Analyst Price Targets for Sol Gel Technologies.
What is the consensus analysts' recommendation for Sol Gel Technologies?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sol Gel Technologies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sol Gel Technologies.
What are Wall Street analysts saying about Sol Gel Technologies stock?
Here are some recent quotes from research analysts about Sol Gel Technologies stock:
- 1. According to Zacks Investment Research, "Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel. " (2/12/2019)
- 2. HC Wainwright analysts commented, "We have valued Sol-Gel based on a discounted cash flow (DCF) analysis. This yields a value of $102M for TWIN, assuming a 50% probability of success, and a $323M valuation for Epsolay, assuming a 60% probability of success." (12/5/2018)
Has Sol Gel Technologies been receiving favorable news coverage?
News headlines about SLGL stock have been trending positive recently, InfoTrie reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sol Gel Technologies earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are some of Sol Gel Technologies' key competitors?
Some companies that are related to Sol Gel Technologies include Zymeworks (ZYME), Collegium Pharmaceutical (COLL), Forty Seven (FTSV), Corium International (CORI), Theratechnologies (THERF), Obseva (OBSV), ZEALAND PHARMA/S (ZEAL), Clementia Pharmaceuticals (CMTA), Odonate Therapeutics (ODT), Cytokinetics (CYTK), Aptorum Group (APM), Innate Pharma (IPHYF), Progenics Pharmaceuticals (PGNX), Five Prime Therapeutics (FPRX) and Osmotica Pharmaceuticals (OSMT).
Who are Sol Gel Technologies' key executives?
Sol Gel Technologies' management team includes the folowing people:
- Dr. Alon Seri-Levy, Co-Founder, CEO & Director (Age 58)
- Mr. Gilad Mamlok, Chief Financial Officer (Age 51)
- Dr. Ofer Toledano, VP of R&D (Age 54)
- Dr. Ofra Levy-Hacham Ph.D., VP of clinical & Regulatory Affairs (Age 53)
- Prof. David Avnir, Co-Founder
When did Sol Gel Technologies IPO?
(SLGL) raised $60 million in an initial public offering (IPO) on Thursday, February 1st 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Jefferies and BMO Capital Markets acted as the underwriters for the IPO and JMP Securities and Raymond James were co-managers.
Who are Sol Gel Technologies' major shareholders?
Sol Gel Technologies' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Delek Group Ltd. (7.56%), Raymond James Financial Services Advisors Inc. (0.24%) and Raymond James & Associates (0.12%).
Which institutional investors are selling Sol Gel Technologies stock?
SLGL stock was sold by a variety of institutional investors in the last quarter, including Raymond James & Associates.
Which institutional investors are buying Sol Gel Technologies stock?
SLGL stock was purchased by a variety of institutional investors in the last quarter, including Delek Group Ltd. and Raymond James Financial Services Advisors Inc..
How do I buy shares of Sol Gel Technologies?
Shares of SLGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sol Gel Technologies' stock price today?
One share of SLGL stock can currently be purchased for approximately $6.69.
How big of a company is Sol Gel Technologies?
Sol Gel Technologies has a market capitalization of $126.59 million and generates $170,000.00 in revenue each year. The company earns $-31,560,000.00 in net income (profit) each year or ($5.02) on an earnings per share basis. Sol Gel Technologies employs 49 workers across the globe.
What is Sol Gel Technologies' official website?
How can I contact Sol Gel Technologies?
Sol Gel Technologies' mailing address is 7 GOLDA MEIR ST.WEIZMANN SCIENCE PARK, NESS ZIONA L3, 7403650. The company can be reached via phone at 972-8931-3433.
MarketBeat Community Rating for Sol Gel Technologies (NASDAQ SLGL)
MarketBeat's community ratings are surveys of what our community members think about Sol Gel Technologies and other stocks. Vote "Outperform" if you believe SLGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLGL will underperform the S&P 500 over the long term. You may vote once every thirty days.
